Analgesic effect of delta-9-tetrahydrocannabinol.
A preliminary trial of oral delta-9-tetrahydrocannabinol (THC) demonstrated an analgesic effect of the drug in patients experiencing cancer pain. Placebo and 5, 10, 15, and 20 mg THC were administered double blind to ten patients. Pain relief significantly superior to placebo was demonstrated at high dose levels (15 and 20 mg). At these levels, substantial sedation and mental clouding were reported.
D000284:Administration, Oral; D000700:Analgesics / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002188:Cannabis / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D008517:Phytotherapy; D010919:Placebos; D013997:Time Factors
D000700:Analgesics; D010919:Placebos; D013759:Dronabinol